257 related articles for article (PubMed ID: 25709446)
1. Nanopharmaceuticals (part 2): products in the pipeline.
Weissig V; Guzman-Villanueva D
Int J Nanomedicine; 2015; 10():1245-57. PubMed ID: 25709446
[TBL] [Abstract][Full Text] [Related]
2. Nanopharmaceuticals (part 1): products on the market.
Weissig V; Pettinger TK; Murdock N
Int J Nanomedicine; 2014; 9():4357-73. PubMed ID: 25258527
[TBL] [Abstract][Full Text] [Related]
3. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Bobo D; Robinson KJ; Islam J; Thurecht KJ; Corrie SR
Pharm Res; 2016 Oct; 33(10):2373-87. PubMed ID: 27299311
[TBL] [Abstract][Full Text] [Related]
5. Towards improved therapies using nanopharmaceuticals: recent patents on pharmaceutical nanoformulations.
Horstkotte E; Odoerfer KI
Recent Pat Food Nutr Agric; 2012 Dec; 4(3):220-44. PubMed ID: 23013408
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
7. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
[TBL] [Abstract][Full Text] [Related]
8. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
Agarwal V; Bajpai M; Sharma A
Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
[TBL] [Abstract][Full Text] [Related]
9. Challenges associated and approaches for successful translation of nanomedicines into commercial products.
Agrahari V; Hiremath P
Nanomedicine (Lond); 2017 Apr; 12(8):819-823. PubMed ID: 28338401
[No Abstract] [Full Text] [Related]
10. Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola CL
P T; 2017 Dec; 42(12):742-755. PubMed ID: 29234213
[TBL] [Abstract][Full Text] [Related]
11. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
[TBL] [Abstract][Full Text] [Related]
12. Nanopharmaceuticals: Tiny challenges for the environmental risk assessment of pharmaceuticals.
Berkner S; Schwirn K; Voelker D
Environ Toxicol Chem; 2016 Apr; 35(4):780-7. PubMed ID: 25931425
[TBL] [Abstract][Full Text] [Related]
13. Formulation aspects of nanopharmaceuticals and nanotechnology I Introduction, biopharmaceutical aspects.
Viktor F; Emese B; Geza J; Istvan A
Acta Pharm Hung; 2016; 86(2):43-52. PubMed ID: 29873962
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine: de novo design of nanodrugs.
Yang Z; Kang SG; Zhou R
Nanoscale; 2014 Jan; 6(2):663-77. PubMed ID: 24305636
[TBL] [Abstract][Full Text] [Related]
15. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
16. Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.
Souto EB; Silva GF; Dias-Ferreira J; Zielinska A; Ventura F; Durazzo A; Lucarini M; Novellino E; Santini A
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32053962
[TBL] [Abstract][Full Text] [Related]
17. Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds.
Rivera Gil P; Hühn D; del Mercato LL; Sasse D; Parak WJ
Pharmacol Res; 2010 Aug; 62(2):115-25. PubMed ID: 20097288
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of novel nanosized formulations used in medicine.
El-Ansary A; Al-Daihan S; Bacha AB; Kotb M
Methods Mol Biol; 2013; 1028():47-74. PubMed ID: 23740113
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines: addressing the scientific and regulatory gap.
Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
